Curcumin and cognition: A randomised, placebo-controlled, double-blind study of community-dwelling older adults

British Journal of Nutrition

Volumn 115, Issue 12, 2016, Pages 2106-2113

  Rainey Smith, Stephanie R ^a,b   Brown, Belinda M ^a,b   Sohrabi, Hamid R ^a,b,c   Shah, Tejal ^a,b   Goozee, Kathryn G ^c,d   Gupta, Veer B ^a,b   Martins, Ralph N ^a,b,c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d McCusker KARVIAH Research Centre   (Australia)

Author keywords

Ageing; Alzheimer's disease; Cognition; Curcumin

Indexed keywords

CURCUMIN; PLACEBO; PLANT EXTRACT;

AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; AGING; CHEMISTRY; COGNITION DISORDERS; COMPLICATION; CURCUMA; DEMENTIA; DRUG EFFECTS; LONGITUDINAL STUDY; MIDDLE AGED; PHYTOTHERAPY;

AGED; AGING; COGNITION; COGNITION DISORDERS; CURCUMA; CURCUMIN; DEMENTIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84964265977     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114516001203     Document Type: Article

References (48)

1. Zhang C, Browne A, Child D, et al. (2010) Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 285, 28472-28480
2. Sikora E, Scapagnini G & Barbagallo M (2010) Curcumin, inflammation, ageing and age-related diseases. Immun Ageing 7, 1
3. Yadav B, Taurin S, Rosengren RJ, et al. (2010) Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg Med Chem 18, 6701-6707
4. Sikora E, Bielak-Zmijewska A, Mosieniak G, et al. (2010) The promise of slow down ageing may come from curcumin. Curr Pharm Des 16, 884-892
5. Aggarwal BB, Sundaram C, Malani N, et al. (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595, 1-75
6. Mutsuga M, Chambers JK, Uchida K, et al. (2012) Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer's brain. J Vet Med Sci 74, 51-57
7. Ma QL, Zuo X, Yang F, et al. (2013) Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 288, 4056-4065
8. Garcia-Alloza M, Borrelli LA, Rozkalne A, et al. (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102, 1095-1104
9. Huang HC, Chang P, Dai XL, et al. (2012) Protective effects of curcumin on amyloid-beta-induced neuronal oxidative damage. Neurochem Res 37, 1584-1597
10. Masters CL, Simms G, Weinman NA, et al. (1985) Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249
11. Kosik KS, Joachim CL & Selkoe DJ (1986) Microtubuleassociated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83, 4044-4048
12. Zotova E, Nicoll JA, Kalaria R, et al. (2010) Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2, 1
13. Akiyama H, Barger S, Barnum S, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421
14. Agostinho P, Cunha RA & Oliveira C (2010) Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 16, 2766-2778
15. Mithu VS, Sarkar B, Bhowmik D, et al. (2014) Curcumin alters the salt bridge-containing turn region in amyloid beta(1-42) aggregates. J Biol Chem 289, 11122-11131
16. Lim GP, Chu T, Yang F, et al. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370-8377
17. Yang F, Lim GP, Begum AN, et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-5901
18. Wang YJ, Thomas P, Zhong JH, et al. (2009) Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 15, 3-14
19. Ma QL, Yang F, Rosario ER, et al. (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089
20. Frautschy SA, Hu W, Kim P, et al. (2001) Phenolic antiinflammatory antioxidant reversal of A-beta induced cognitive deficits and neuropathology. Neurobiol Aging 22, 991-1003
21. Ng TP, Chiam PC, Lee T, et al. (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164, 898-906
22. Baum L, Lam CW, Cheung SK, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110-113
23. Ringman JM, Frautschy SA, Teng E, et al. (2012) Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4, 43
24. Cox KH, Pipingas A & Scholey AB (2015) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol 29, 642-651
25. Gota VS, Maru GB, Soni TG, et al. (2010) Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58, 2095-2099
26. DiSilvestro RA, Joseph E, Zhao S, et al. (2012) Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11, 79
27. Villemagne VL, Burnham S, Bourgeat P, et al. (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12, 357-367
28. Antony B, Merina B, Iyer VS, et al. (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70, 445-449
29. Ware JE Jr & Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30, 473-483
30. Rossetti HC, Lacritz LH, Cullum CM, et al. (2011) Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 77, 1272-1275
31. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: APA
32. Lovibond SH & Lovibond PF (1993) Manual for the Depression Anxiety Stress Scales (DASS), Australia Psychology Foundation Monograph. Sydney: Psychology Foundation
33. Beardsall L (1998) Development of the Cambridge Contextual Reading Test for improving the estimation of premorbid verbal intelligence in older persons with dementia. Br J Clin Psychol 37, 229-240
34. Lovibond PF & Lovibond SH (1995) The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 33, 335-343
35. Smith G, Della Sala S, Logie RH, et al. (2000) Prospective and retrospective memory in normal ageing and dementia: a questionnaire study. Memory 8, 311-321
36. Nasreddine ZS, Phillips NA, Bedirian V, et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53, 695-699
37. Spreen O & Strauss E (1998) A Compendium of Neuropsychological Tests. Administration, Norms, and Commentary. New York: Oxford University Press
38. Lezak MD, Howieson DB & Loring DW (2004) Neuropsychological Assessment. New York: Oxford University Press
39. Wechsler D (1981) Wechsler Adult Intelligence Scale-Revised (WAIS-R). New York: Psychological Corporation
40. Agrawal R, Mishra B, Tyagi E, et al. (2010) Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 61, 247-252
41. Dong S, Zeng Q, Mitchell ES, et al. (2012) Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLOS ONE 7, e31211
42. Yu SY, Zhang M, Luo J, et al. (2013) Curcumin ameliorates memory deficits via neuronal nitric oxide synthase in aged mice. Prog Neuropsychopharmacol Biol Psychiatry 45, 47-53
43. Maruff P, Collie A, Darby D, et al. (2004) Subtle memory decline over 12 months in mild cognitive impairment. Dement Geriatr Cogn Disord 18, 342-348
44. Bergman J, Miodownik C, Bersudsky Y, et al. (2013) Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin Neuropharmacol 36, 73-77
45. Lopresti AL, Maes M, Maker GL, et al. (2014) Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord 167, 368-375
46. Sanmukhani J, Satodia V, Trivedi J, et al. (2014) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 28, 579-585
47. Kulkarni SK, Bhutani MK & Bishnoi M (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 201, 435-442
48. Huang Z, Zhong XM, Li ZY, et al. (2011) Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett 493, 145-148.